CJC 1295 with DAC vs Without DAC and Which One You Should Actually Use

The version most people choose is the one that requires fewer injections, and that logic makes sense on the surface but misses what the choice is actually about.

CJC 1295 is something called a GHRH analog, which means it mimics the signal your hypothalamus sends to your pituitary gland to release growth hormone. The idea behind using it instead of injecting growth hormone directly is that you are working through your body's own machinery rather than bypassing it, and that distinction turns out to matter more than most people realize.

To understand why, you need the full chain first. Your hypothalamus pulses GHRH in rhythmic bursts throughout the day, each burst tells your pituitary to release a wave of growth hormone, and those waves travel through your blood to trigger effects like fat breakdown and tissue repair. Between those waves, growth hormone drops back down close to zero, and then the next pulse fires. That rhythm is not a quirk of biology. It is how the system is designed to work, and the effects you are actually after depend on it.

CJC 1295 without DAC fits into that rhythm. Its half life is around 30 minutes, so you inject it, it triggers a burst from your pituitary, and then it clears out before your next natural pulse is scheduled to fire. Your body's own GHRH keeps running its rhythm between your doses and the pattern of highs and lows stays roughly intact. You are essentially adding extra pulses to a system that is still operating the way it should.

DAC stands for drug affinity complex, and it is a modification that causes CJC 1295 to bind to something called albumin, which is a protein that circulates in your blood and normally carries other molecules around. When CJC 1295 binds to albumin, it stops being filtered out of your blood quickly, and its half life extends from about 30 minutes to somewhere between 5.8 and 8.1 days depending on the individual. That is the entire appeal: inject once or twice a week instead of multiple times a day.

But here is what that extended half life actually does. A study by Ionescu and Frohman tested CJC 1295 with DAC in humans and found that pulsatile secretion of growth hormone was preserved. The pulses still fired at roughly normal frequency and magnitude. That sounds like a win until you see the other number: the baseline level of growth hormone between those pulses, what you could call the valley between waves, was elevated 7.5 times above normal. The peaks kept coming. The valleys disappeared.

Think of it like a tide that never fully goes out. Your high tide still comes in, but because the baseline water level is permanently raised, what should be low tide is still covering the beach. The system is still cycling, but the low point that the cycle depends on no longer exists.

That low point matters because your pituitary and the receptors it uses to receive GHRH signals are regulated by what is called homologous downregulation, which is the process where a receptor reduces its own sensitivity in response to persistent stimulation. Research by Aleppo and colleagues showed that continuous GHRH exposure for just four hours reduced GHRH receptor expression to between 49 and 54 percent of baseline, and the effect was both dose dependent and driven by a messenger molecule called cAMP. The valleys in normal pulsatile release give those receptors time to reset between signals. Remove the valleys and the receptors start pulling back.

The more important question though is whether the pattern difference translates to real physiological outcomes, and there is direct evidence that it does. A study by Surya and colleagues tested pulsatile versus continuous growth hormone delivery in humans and measured what happened to lipolysis, which is the process of breaking down stored fat for fuel. Pulsatile delivery raised lipolysis from a baseline of 4.1 up to 7.1 micromoles per kilogram per minute, nearly doubling it. Continuous delivery produced a final value of 4.8, which was not statistically different from the baseline of 4.1. The same growth hormone exposure, just delivered in a different pattern, produced completely opposite results.

That single comparison is the reason the DAC decision matters as much as it does. The reason you chose a secretagogue over direct growth hormone in the first place was presumably to preserve pulsatility, to work with the body's system rather than override it. DAC preserves the pulses but eliminates the valleys, and the evidence suggests the valleys are where the pattern actually gets its effect.

If you want continuous growth hormone elevation, you can get that from direct growth hormone injections with a known dose, decades of pharmacokinetic data, and precise control over timing. DAC puts you in a middle position where you no longer have the pulsatile advantage that made a secretagogue worth choosing, and you also do not have the precision that makes direct growth hormone worth choosing. You traded both for fewer injections.

CJC 1295 without DAC is the version where the injection frequency is the cost you pay to keep the mechanism working the way it needs to. The short half life is not a flaw to be engineered around. It is what allows the rhythm to stay intact.

---

References

1. Surya S et al. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. J Clin Endocrinol Metab. 2009;948:2828-2834 — Pulsatile GH nearly doubled lipolysis 7.1 vs 4.1 baseline, continuous was not significantly different from baseline 4.8 vs 4.1. Source
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;9112:4792-4797 — CJC-1295 DAC preserved pulse frequency and magnitude but elevated basal trough GH 7.5-fold. Source
3. Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;913:799-805 — CJC-1295 DAC half-life 5.8-8.1 days due to albumin binding. Source
4. Aleppo G et al. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology. 1997;1383:1058-1065 — Continuous GHRH exposure for 4 hours reduced GHRH receptor mRNA to 49-54% of baseline, dose-dependent and cAMP-mediated. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness